Skip to main content
AVANOS MEDICAL, INC. logo

AVANOS MEDICAL, INC. — Investor Relations & Filings

Ticker · AVNS ISIN · US40650V1008 LEI · 549300YCXWOM7NEWMQ58 US Manufacturing
Open in API
Filings indexed 673 across all filing types
Latest filing 2022-01-26 Major Shareholding Noti…
Country US United States of America
Listing US AVNS

About AVANOS MEDICAL, INC.

https://avanos.com/

Avanos Medical, Inc. is a medical technology company that develops, manufactures, and markets medical device solutions. The company's portfolio is focused on two primary segments: Pain Management & Recovery and Enteral Feeding. The Pain Management & Recovery division provides a range of non-opioid therapies and solutions for managing chronic and post-surgical pain, targeting specialties such as anesthesiology, orthopedics, and interventional pain management. The Enteral Feeding division offers a comprehensive portfolio of nutrition delivery systems and products for a wide spectrum of patients, from neonates and pediatrics to adults, supporting healthcare providers in critical and long-term care settings. The company is focused on delivering clinically superior solutions that improve patient outcomes and facilitate recovery.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-01-26 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 20, 2022, reporting the completion of a merger acquisition and the incurrence of new term loans to finance the transaction. It includes detailed descriptions of the merger agreement, financing terms, and references to attached exhibits such as the merger agreement and credit agreements. The content focuses on merger completion and financing updates rather than full financial statements or earnings results. Therefore, it fits best under the category of Capital/Financing Update (CAP) due to the detailed disclosure of new debt financing and acquisition funding. The document length (7462 characters) and detailed content confirm it is not a brief announcement or a certification but a substantive report on financing and acquisition events.
2022-01-21 English
Regulatory Filings 2022
Regulatory Filings Classification · 90% confidence The provided document text appears to be heavily encoded or corrupted, containing mostly non-readable characters and no discernible content related to any specific financial filing type. There are no clear references to regulatory bodies, report titles, fiscal periods, or keywords that would indicate the nature of the document. Given the lack of meaningful content and the inability to identify any specific filing type, the document should be classified under the fallback category for miscellaneous or unclear filings, which is Regulatory Filings (RNS). The document length is sufficient to rule out a simple announcement, but the content does not match any other specific category.
2022-01-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 11, 2022, by Avanos Medical, Inc. It primarily announces the posting of an investor presentation related to the J.P. Morgan Healthcare Conference. The text explicitly states that the presentation is attached as Exhibit 99.1 and is being furnished, not filed, and that the information is not subject to certain filing liabilities. The document is short (4435 characters) and serves as a notice of the availability of the investor presentation rather than the presentation itself or a detailed financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain substantive financial data or the full investor presentation text itself.
2022-01-11 English
Annual Report 2022
Annual Report Classification · 95% confidence The document is a detailed response letter from Avanos Medical, Inc. to the SEC staff regarding comments on their previously filed Form 10-K for the fiscal year ended December 31, 2020. It discusses specific accounting and disclosure issues related to the 10-K filing, including management's discussion and analysis (MD&A) and revenue recognition policies. The letter includes detailed explanations and proposed revisions to the 10-K disclosures, exhibits with expanded MD&A and accounting policy notes, and references to ASC accounting standards. The document is lengthy (15,000 characters) and contains substantive financial and operational information related to the annual report. It is not merely an announcement or certification but a comprehensive response addressing the content of the 10-K report. Therefore, the document should be classified as an Annual Report (10-K).
2022-01-06 English
FORM 4
Director's Dealing
2022-01-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.